Quest Laboratories Share Price & Earnings Call Analysis
- Market cap
- ₹143 Cr
- P/E
- 9.65
- ROE
- 16.64%
- PEG
- 0.22
- Price to sales
- 1.28
- Debt to equity
- 0.08
- 52W high / low
- ₹152 / ₹74.1
- Sales growth (5Y)
- 29.79%
- EBITDA margin
- 16.32%
- Net profit margin
- 13.30%
- Promoter holding
- 66.78%
- Sales (last year)
- ₹112 Cr
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Quest Laboratories.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Quest Laboratories
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Quest Laboratories
Quarterly Results
Quarter-by-quarter operating performance
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 15.25 | 27.37 | 14.84 | 46.45 | 23.18 | 25.62 | 30.61 | 32.40 |
| Expenses + | 13.47 | 18.56 | 14.18 | 45.64 | 19.36 | 22.24 | 23.70 | 28.26 |
| Operating Profit | 1.78 | 8.81 | 0.66 | 0.81 | 3.82 | 3.38 | 6.91 | 4.14 |
| OPM % | 11.67% | 32.19% | 4.45% | 1.74% | 16.48% | 13.19% | 22.57% | 12.78% |
| Other Income + | 0.16 | 0.68 | 0.30 | 3.41 | 1.85 | 1.42 | 0.57 | -1.31 |
| Interest | 0.13 | 0.37 | 0.04 | 0.37 | 0.64 | 0.58 | 0.47 | 0.16 |
| Depreciation | 0.15 | 0.14 | 0.15 | 0.19 | 0.21 | 0.21 | 0.20 | 0.21 |
| Profit before tax | 1.66 | 8.98 | 0.77 | 3.66 | 4.82 | 4.01 | 6.81 | 2.46 |
| Tax % | 11.45% | 32.41% | 0.00% | 47.27% | 14.94% | 0.00% | 40.82% | -16.67% |
| Net Profit + | 1.48 | 6.06 | 0.78 | 1.94 | 4.10 | 4.02 | 4.03 | 2.87 |
| EPS in Rs | 0.90 | 3.70 | 0.48 | 1.18 | 2.50 | 2.45 | 2.46 | 1.75 |
Financials of Quest Laboratories
Profit & Loss
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 30 | 59 | 62 | 83 | 104 | 112 |
| Expenses + | 29 | 53 | 54 | 67 | 88 | 94 |
| Operating Profit | 1 | 6 | 8 | 16 | 16 | 18 |
| OPM % | 5% | 11% | 13% | 19% | 15% | 16% |
| Other Income + | 0 | 0 | 0 | 0 | 4 | 3 |
| Interest | 0 | 0 | 1 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 19 | 18 |
| Tax % | 18% | 29% | 28% | 30% | 27% | 17% |
| Net Profit + | 1 | 4 | 5 | 10 | 14 | 15 |
| EPS in Rs | 8.45 | 8.28 | 9.17 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Quest Laboratories
Balance Sheet
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 65 | 80 |
| Borrowings + | 3 | 3 | 4 | 5 | 30 | 8 |
| Other Liabilities + | 9 | 22 | 28 | 27 | 10 | 6 |
| Total Liabilities | 18 | 35 | 47 | 61 | 122 | 111 |
| Fixed Assets + | 6 | 7 | 10 | 10 | 12 | 15 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 7 | 52 | 16 |
| Other Assets + | 12 | 27 | 37 | 44 | 58 | 79 |
| Total Assets | 18 | 35 | 47 | 61 | 122 | 111 |
Financials of Quest Laboratories
Cash Flows
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1 | 3 | 4 | 3 | -23 | |
| Cash from Investing Activity + | -1 | -2 | -4 | -5 | -44 | |
| Cash from Financing Activity + | 0 | -0 | 0 | 2 | 67 | |
| Net Cash Flow | -0 | 1 | 0 | 0 | -0 | |
| Free Cash Flow | -0 | 2 | 1 | 2 | -27 | |
| CFO/OP | 103% | 57% | 72% | 46% | -120% |
Financials of Quest Laboratories
Ratios
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 108 | 105 | 118 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 | 163 |
| Days Payable | 119 | 140 | 215 | 144 | 26 | 24 |
| Cash Conversion Cycle | 3 | 4 | 1 | 77 | 178 | 258 |
| Working Capital Days | 9 | 14 | 27 | 58 | 72 | 258 |
| ROCE % | 55% | 47% | 57% | 27% | 18% |
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.